The company reported top-line results for the first of two identical studies that compared its treatment, Androxal, with the leading FDA-approved Androgel. Androxal showed superiority in multiple assessments, specifically the two co-primary endpoints of percent change from baseline in average sperm concentration and percent of subjects considered to be responders.
The study defines a responder as "an individual achieving a 24-hour average testosterone in the normal range with associated average sperm concentration >= 10 million/mL," according to the press release.
Androxal also showed superiority in secondary endpoints, including change in the key pituitary signaling hormones LH and FSH.
The stock was up 10.21% to $20.07 at 9:59 a.m. More than 2.1 million shares had changed hands, compared to the average volume of 258,220.RPRX data by YCharts
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.